We have investigated the expression of two estrogen receptor beta (ERbeta) isoforms, ERbeta1 and ERbeta5, which activate gene transcription independent of estrogen or growth factors, in ERalpha-negative breast cancer tissues. We report here, for the first time, that ERalpha-negative tissues express significant levels of ERbeta1 and ERbeta5, and their expression levels are not different from levels in ERalpha positive tumors. However, significant differences exist between the two racial groups, African American and Caucasian, in that the patients from the former group express higher levels of ERbeta1 and ERbeta5 but not ERalpha. These two transcription factors could be potential molecular targets for designing chemopreventive drugs to treat ERalpha-negative breast cancers.
No takes yet. Share an insight, caveat, or question.
Poola et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: